Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 2
1975 1
1977 1
1978 1
1983 1
1984 1
1985 1
1988 5
1989 4
1991 4
1992 6
1993 12
1994 10
1995 13
1996 22
1997 30
1998 27
1999 22
2000 26
2001 22
2002 16
2003 21
2004 21
2005 24
2006 20
2007 15
2008 11
2009 12
2010 7
2011 16
2012 19
2013 12
2014 14
2015 15
2016 31
2017 14
2018 19
2019 17
2020 9
2021 21
2022 12
2023 19
2024 12
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 9829585

550 results

Results by year

Filters applied: . Clear all
Page 1
Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R. Virgolini I, et al. Curr Pharm Des. 2002;8(20):1781-807. doi: 10.2174/1381612023393756. Curr Pharm Des. 2002. PMID: 12171531 Review.
Vasoactive intestinal peptide receptor scintigraphy.
Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, Li S, Scheithauer W, Niederle B, Valent P, et al. Virgolini I, et al. J Nucl Med. 1995 Oct;36(10):1732-9. J Nucl Med. 1995. PMID: 7562036 Free article.
New trends in peptide receptor radioligands.
Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R. Virgolini I, et al. Q J Nucl Med. 2001 Jun;45(2):153-9. Q J Nucl Med. 2001. PMID: 11476164 Review.
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A, Förster GJ, Reber H, Buchholz HG, Arnold R, Göke B, Weber MM, Wiedenmann B, Pauwels S, Haus U, Bouterfa H, Bartenstein P. Helisch A, et al. Eur J Nucl Med Mol Imaging. 2004 Oct;31(10):1386-92. doi: 10.1007/s00259-004-1561-6. Epub 2004 Jun 3. Eur J Nucl Med Mol Imaging. 2004. PMID: 15175836 Clinical Trial.
"MAURITIUS": tumour dose in patients with advanced carcinoma.
Virgolini I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Smith-Jones P. Virgolini I, et al. Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S227-30. Ital J Gastroenterol Hepatol. 1999. PMID: 10604137 Clinical Trial.
550 results